Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn ’s Disease

ConclusionsThe model supports the use of Inflecta® for Crohn ’s disease in the UK, and provides a framework for the quantitative evaluation of biosimilars in the context of a health technology assessment. Value-based pricing using this methodology could protect health systems from the potential risks of biosimilars where they are untested in the approved po pulations.
Source: PharmacoEconomics - Category: Health Management Source Type: research